Linking To And Excerpting From Google Search “Antisense Oligonucleosides”

Today, I review, link to, and list some of the results from a Google Search “Antisense Oligonucleosides”. Below are some of the results found on that web page. It is worth reviewing the entire page’s resources.

AI Overview

Antisense oligonucleotides (ASOs) are short, synthetic strings of DNA or RNA designed to bind to specific RNA targets via complementary base-pairing. By doing so, they alter how the genetic instructions are read, allowing scientists to turn off specific disease-causing genes, reduce toxic proteins, or correct splicing errors. 

Nature +2

ASOs have revolutionized the treatment of severe genetic, neuromuscular, and neurodegenerative conditions. 

Nature +2

Mechanism of Action (How they work)

ASOs act on the intermediate RNA step before it is translated into a protein. They function primarily in three ways: [1, 2]

• • Knockdown (Degradation): The ASO binds to the target mRNA, which triggers naturally occurring cellular enzymes (like RNase H) to destroy the RNA before it can be used to build a harmful protein. [1, 2, 3]

• Splice Modulation: The ASO attaches to the pre-mRNA to block or expose specific splice sites. This forces the cell to skip or include certain sections (exons), allowing the body to produce a functional protein instead of a broken one. [1, 2]
• Translation Arrest: The ASO blocks ribosomes from attaching to the mRNA, essentially halting the production of a specific protein. [1, 2]

Clinical Applications

ASO therapies are highly versatile and particularly useful for rare, previously “undruggable” diseases. Several FDA-approved ASOs are actively used in clinics: [1]

• Spinal Muscular Atrophy (SMA): Nusinersen (Spinraza) is a splice-modulating ASO that helps the body produce the survival motor neuron (SMN) protein, which is critical for muscle control. [1, 2]
• Duchenne Muscular Dystrophy (DMD): ASOs like Eteplirsen (Exondys 51) and Golodirsen (Vyondys 53) are designed to skip specific exons in the dystrophin gene, allowing the body to produce a truncated but still functional dystrophin protein. [1, 2, 3]
• Amyotrophic Lateral Sclerosis (ALS): Tofersen (Qalsody) is an ASO that targets the SOD1 gene, reducing the toxic protein buildup that causes motor neuron loss in some familial cases of ALS. [1, 2, 3, 4]
• Other Conditions: ASOs have also been approved to treat severe hypercholesterolemia (e.g., Mipomersen), cytomegalovirus retinitis (Fomivirsen, the first approved ASO), and certain rare genetic eye diseases. [1, 2, 3, 4, 5]

Advantages & Limitations

• Precision: Because they are based on sequence-specific targeting, they can be rapidly tailored to individual genetic mutations (as seen in bespoke “N-of-1” treatments like the famous drug Milasen). [1, 2, 3]
• Limitations: ASOs are fragile and can be quickly broken down by the body’s natural enzymes if not chemically modified. Consequently, delivering them to specific tissues (like the central nervous system) requires specialized procedures, such as spinal taps, rather than simple oral pills. They also carry a risk of off-target effects or immune reactions. [1, 2, 3, 4, 5]

For comprehensive clinical trial data and up-to-date research on ASO therapies, you can consult the National Center for Advancing Translational Sciences (NCATS) Toolkit or review emerging studies on PubMed Central.